← Leaderboards
Mark D Noble
University Of Rochester
$9,749,494
Attributed
$9,942,980
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $868.5K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,942,980 · 9
By mechanism
R01$9,095,464 · 6
R21$746,948 · 2
P01$100,568 · 1
Top collaborators
- Jonathan Ian Leckenby2 shared
Most similar at University Of Rochester
Same institution · by research overlap
- Gregory Gordon Tall$9,812,841
- Jonathan Ian Leckenby$193,487
Others in their field
Top investigators on “Stem Cells”
- Mary M Horowitz · Medical College Of Wisconsin$220,248,453
- David Heimbrook · Leidos Biomedical Research, Inc.$161,931,307
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$73,044,559
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$70,591,644
- Michelle M Le Beau · University Of Chicago$70,506,423
Research focus
Stem CellsOligodendrogliaNeuronsPathway InteractionsClinically RelevantOxidation-ReductionCell DeathCellsMalignant NeoplasmsCell DivisionBiologicalChemotherapeutic AgentCell PhysiologyMyelinationNormal CellBaseTissue /Cell CultureTherapeutic AgentsNeurologicReceptor Protein-Tyrosine KinasesCancer CellReceptorGenerationsMyelin
Grant awards (36)
Prevention and treatment of paclitaxel-induced peripheral neuropathy$170,988
R21 · FY2024 · CA · contact PI
Prevention and treatment of paclitaxel-induced peripheral neuropathy$215,985
R21 · FY2023 · CA · contact PI
Mechanism-based drug repurposing and novel treatments for glioblastoma$352,275
R01 · FY2021 · CA · contact PI
Mechanism-based drug repurposing and novel treatments for glioblastoma$352,275
R01 · FY2020 · CA · contact PI
Mechanism-based drug repurposing and novel treatments for glioblastoma$230,170
R01 · FY2020 · CA · contact PI
Mechanism-based drug repurposing and novel treatments for glioblastoma$341,706
R01 · FY2019 · CA · contact PI
Mechanism-based drug repurposing and novel treatments for glioblastoma$352,275
R01 · FY2018 · CA · contact PI
Mechanism-based drug repurposing and novel treatments for glioblastoma$351,894
R01 · FY2017 · CA · contact PI
CNS vulnerability to systemic chemotherapy: Causes and prevention$309,964
R01 · FY2012 · CA · contact PI
CNS vulnerability to systemic chemotherapy: Causes and prevention$309,964
R01 · FY2011 · CA · contact PI
Low-level toxicant perturbation of neural cell function$349,036
R01 · FY2010 · ES · contact PI
CNS vulnerability to systemic chemotherapy: Causes and prevention$319,550
R01 · FY2010 · CA · contact PI
Low-level toxicant perturbation of neural cell function$352,562
R01 · FY2009 · ES · contact PI
CNS vulnerability to systemic chemotherapy: Causes and prevention$319,550
R01 · FY2009 · CA · contact PI
White matter damage in Alzheimer?s disease: New cellular targets and mechanisms$163,625
R21 · FY2009 · AG · contact PI
Low-level toxicant perturbation of neural cell function$352,562
R01 · FY2008 · ES · contact PI
CNS vulnerability to systemic chemotherapy: Causes and prevention$319,550
R01 · FY2008 · CA · contact PI
White matter damage in Alzheimer?s disease: New cellular targets and mechanisms$196,350
R21 · FY2008 · AG · contact PI
Low-level toxicant perturbation of neural cell function$359,756
R01 · FY2007 · ES · contact PI
Low-level toxicant perturbation of neural cell function$370,500
R01 · FY2006 · ES · contact PI
Oligodendrocytes &precursors: toxicity of chemotherapy$374,063
R01 · FY2005 · NS
CNS PRECURSOR CELL DYSFUNCTION IN DEVELOPMENTAL MALADIES$322,988
R01 · FY2005 · HD
Oligodendrocytes &precursors: toxicity of chemotherapy$374,063
R01 · FY2004 · NS
CNS PRECURSOR CELL DYSFUNCTION IN DEVELOPMENTAL MALADIES$322,988
R01 · FY2004 · HD
Oligodendrocytes &precursors: toxicity of chemotherapy$374,063
R01 · FY2003 · NS
CNS PRECURSOR CELL DYSFUNCTION IN DEVELOPMENTAL MALADIES$322,988
R01 · FY2003 · HD
Oligodendrocytes &precursors: toxicity of chemotherapy$374,854
R01 · FY2002 · NS
CNS PRECURSOR CELL DYSFUNCTION IN DEVELOPMENTAL MALADIES$322,988
R01 · FY2002 · HD
CORE--TISSUE PROCUREMENT AND CULTURE$0
P01 · FY2002 · CA
CNS PRECURSOR CELL DYSFUNCTION IN DEVELOPMENTAL MALADIES$322,988
R01 · FY2001 · HD
PRECURSOR CELL RENEWAL, OLIGODENDROCYTES &REMYELINATION$307,896
R01 · FY2001 · NS
CORE--TISSUE PROCUREMENT AND CULTURE$0
P01 · FY2001 · CA
PRECURSOR CELL RENEWAL, OLIGODENDROCYTES &REMYELINATION$145,805
R01 · FY2000 · NS
PRECURSOR CELL RENEWAL, OLIGODENDROCYTES &REMYELINATION$136,191
R01 · FY2000 · NS
CORE--TISSUE PROCUREMENT AND CULTURE$100,568
P01 · FY2000 · CA
PRECURSOR CELL RENEWAL, OLIGODENDROCYTES &REMYELINATION$50,000
R01 · FY2000 · NS